Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: A Randomized, Multi-Center, Placebo-Controlled Clinical Trial (Study OS440-3004)
Background: Arbaclofen, the active R-enantiomer of baclofen, a racemic g-aminobutyric acid-B (GABAB) receptor agonist, has been a mainstay...
Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: An Open-Label Safety Study (Study OS440-3005)
Background: Despite pharmacologic therapy, people with multiple sclerosis (MS) often experience spasticity, which can worsen with longer...
Arbaclofen Extended-Release for Spasticity in Multiple Sclerosis: Responder Analysis of a Phase 3 Randomized, Placebo-Controlled Clinical Study OS440-3004
Background: Arbaclofen is the active R-enantiomer of racemic baclofen. Arbaclofen extended-release (ER) tablets have demonstrated efficacy...
Bad Lettuce? Frozen Vegetables? Undercooked Steak? Case Report of Systemic Listeria Monocytogenes Infection in a Patient on Dimethyl Fumarate
Background: The use of disease modifying treatments (DMTs) in multiple sclerosis (MS) has been well studied and has shown to reduce...
Stakeholder Recommendations for a Dyadic Physical Activity Intervention for People with Moderate-to-Severe Multiple Sclerosis and Their Care-Partners: A Modified e-Delphi Study.
Background: People with moderate-to-severe multiple sclerosis (MS) and their family caregivers do not engage in sufficient physical...
Recently Diagnosed Early-Stage RRMS: Neda, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Background: Early treatment of multiple sclerosis (MS) and rapid onset of therapeutic effect provide long-term benefits on disease...